KARPAS 231 Human B-cell Leukaemia cell line
KARPAS 231 Human B-cell Leukaemia cell line useful in oncology research, developed at the University of Cambridge.
Technology No. KAR-6344-19
Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Enquires to either organisation are welcomed.
-
swap_vertical_circlelibrary_booksReferences (3)
- E Nacheva, M J Dyer, P Fischer, G Stranks, J M Heward, R E Marcus, C Grace, A Karpas (05-01-1993), https://pubmed.ncbi.nlm.nih.gov/8324225/, blood, 82, 231-240
- S Galiègue Zouitina, S Quief, M P Hildebrand, C Denis, G Lecocq, M Collyn-d'Hooghe, C Bastard, M Yuille, M J Dyer, J P Kerckaert (10-04-1996), The B cell transcriptional coactivator BOB1/OBF1 gene fuses to the LAZ3/BCL6 gene by t(3;11)(q27;q23.1) chromosomal translocation in a B cell leukemia line (Karpas 231), Leukemia, 4, 579-587
- T G Willis, D M Jadayel, L J Coignet, M Abdul-Rauf, J G Treleaven, D Catovsky, M J Dyer (15-09-1997), Rapid molecular cloning of rearrangements of the IGHJ locus using long-distance inverse polymerase chain reaction, Blood, 90, 2456-2464
-
swap_vertical_circlecloud_downloadSupporting documents (1)Product brochureKARPAS 231 Human B-cell Leukaemia cell line.pdfAdditional files may be available once you've completed the transaction for this product. If you've already done so, please log into your account and visit My account / Downloads section to view them.
Sign up to our newsletter
If you would like to keep up to date with the latest opportunities, please sign up to our newsletter.